| 标题 |
 The changing treatment landscape of EGFR-mutant non-small-cell lung cancer EGFR突变型非小细胞肺癌治疗前景的变化
相关领域
医学
埃罗替尼
肺癌
肿瘤科
靶向治疗
酪氨酸激酶
癌症
癌症研究
表皮生长因子受体
内科学
受体
|
| 网址 | |
| DOI | |
| 其它 |
Abstract The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central nervous system penetrance, are the standard-of-care first-line treatment for advanced-stage EGFR-mutant NSCLC. Rational combinations of third-generation EGFR TKIs with anti-angiogenic drugs, chemotherapy, the EGFR-MET bispecific antibody amivantamab or local tumour ablation are being investigated as strategies to delay drug resistance and increase clinical benefit. Furthermore, EGFR TKIs are being evaluated in patients with earl |
| 求助人 | |
| 下载 | 求助已完成，仅限求助人下载。 |
|
温馨提示：该文献已被科研通 学术中心 收录，前往查看
科研通『学术中心』是文献索引库，收集文献的基本信息（如标题、摘要、期刊、作者、被引量等），不提供下载功能。如需下载文献全文，请通过文献求助获取。
|
cctv18
彭于彦祖
一一
maox1aoxin
monere
zho
小鱼爱吃肉
背带裤打篮球
港岛妹妹
坚强的广山
嗯哼
tuanheqi
pluto
36456657
带头大哥
子车茗
完美的天空
不配.
寻道图强
竹筏过海
皖公网安备34019202002308
